Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Milestone Pharmaceuticals Inc
MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. Address: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Analytics
Objectif de Cours de WallStreet
10.25 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés MIST
Analyse des dividendes MIST
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes MIST
Valorisation des titres MIST
financières MIST
Résultats | 2019 | Dynamique |